Stoke Therapeutics Inc
NASDAQ:STOK
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
3.79
17.52
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one STOK stock under the Base Case scenario is 6.14 USD. Compared to the current market price of 11.43 USD, Stoke Therapeutics Inc is Overvalued by 46%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Stoke Therapeutics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for STOK cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Stoke Therapeutics Inc
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Stoke Therapeutics Inc
Balance Sheet Decomposition
Stoke Therapeutics Inc
Current Assets | 253.6m |
Cash & Short-Term Investments | 239.2m |
Receivables | 691k |
Other Current Assets | 13.7m |
Non-Current Assets | 39.7m |
Long-Term Investments | 30m |
PP&E | 9.3m |
Other Non-Current Assets | 494k |
Current Liabilities | 49.9m |
Accounts Payable | 2.5m |
Accrued Liabilities | 15.2m |
Other Current Liabilities | 32.2m |
Non-Current Liabilities | 11.3m |
Other Non-Current Liabilities | 11.3m |
Earnings Waterfall
Stoke Therapeutics Inc
Revenue
|
16.7m
USD
|
Operating Expenses
|
-134m
USD
|
Operating Income
|
-117.3m
USD
|
Other Expenses
|
11.8m
USD
|
Net Income
|
-105.5m
USD
|
Free Cash Flow Analysis
Stoke Therapeutics Inc
USD | |
Free Cash Flow | USD |
STOK Profitability Score
Profitability Due Diligence
Stoke Therapeutics Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
Stoke Therapeutics Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
STOK Solvency Score
Solvency Due Diligence
Stoke Therapeutics Inc's solvency score is 71/100. The higher the solvency score, the more solvent the company is.
Score
Stoke Therapeutics Inc's solvency score is 71/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
STOK Price Targets Summary
Stoke Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for STOK is 22.73 USD with a low forecast of 15.15 USD and a high forecast of 36.75 USD.
Dividends
Current shareholder yield for STOK is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
STOK Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. The company is headquartered in Bedford, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2019-06-19. The company focuses to treat the underlying causes of severe genetic diseases by upregulating protein expression. The company is developing antisense oligonucleotide (ASO) medicines that target ribonucleic acid (RNA) and modulate precursor-messenger RNA (pre-mRNA) splicing to upregulate protein expression where needed and with appropriate specificity to near normal levels. The company focuses to develop the precision medicine platform to target the underlying cause of a spectrum of genetic diseases in which the patient has healthy copy of a gene and mutated copy that fails to produce a protein essential to health. The company utilizes its technology platform, Targeted Augmentation of Nuclear Gene Output (TANGO) to design ASOs to upregulate the expression of protein by individual genes in a patient. Its product candidate, STK-001, is offered to treat Dravet syndrome. Its research platform is designed to address protein deficiency.
Contact
IPO
Employees
Officers
The intrinsic value of one STOK stock under the Base Case scenario is 6.14 USD.
Compared to the current market price of 11.43 USD, Stoke Therapeutics Inc is Overvalued by 46%.